Reported 2 months ago
Novo Nordisk's CFO, Karsten Munk Knudsen, announced a significant scaling of Wegovy's supply as demand currently outstrips supply, although the company missed its second-quarter revenue target. Despite this, they reported a 25% growth in the first half of the year and raised their full-year outlook. Knudsen emphasized that they are already maximizing production capabilities.
Source: YAHOO